Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai to roll out two OTC drugs
Selbelle brand lineup comprises range of OTC products to relieve weakness of the stomach associated with aging or other factors. New Selbelle which is a combination of lipase
Selbelle brand lineup comprises range of OTC products to relieve weakness of the stomach associated with aging or other factors. New Selbelle which is a combination of lipase
As per the terms of the deal, Evotech is eligible to pay a sum of $10m as an upfront payment from Roche. Additionally, Evotec is eligible to get
The protein free media improves safety and stability in cultivation of cell-lines for manufacturing viral-based vaccines. The agreement is in line with exploring the extended patent application filed
JAK2 inhibitor, is Lilly’s early stage investigational proprietarycompound, targets the Janus kinase 2 (JAK2) gene, which has been shown to play a role in myeloproliferative neoplasms. The new
The issued patents cover the class of selective 5-HT compounds of Suven that are being developed to treat cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention
The product is based on BLIS K12, which supports the body’s immune system and provides natural and active defense against bacterial imbalance in the mouth, fighting antagonistic bacteria
Esomeprazole is a generic bio-equivalent version of the product Nexium in the UK. Esomeprazole is used to treat dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and
Under the deal, both the parties have signed a Joint Statement on the role of pharmacists in tuberculosis care and control. The agreement aims to increase awareness of
Evec is a developer of a range of human monoclonal antibodies in multiple therapeutic areas, including cancer, inflammatory diseases and infectious diseases. Astellas will pay a sum of
Discovered by PTC, ataluren is an experimental protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense